Astragaloside IV suppresses transforming growth factor-β1-induced epithelial–mesenchymal transition through inhibition of Wnt/β-catenin pathway in glioma U251 cells. Issue 7 (2nd July 2020)

• Record Type: Journal Article
• Authors: Han, Jinming; Shen, Xiaohan; Zhang, Yong; Wang, Suying; Zhou, Leijie
• Is Part Of: Bioscience, biotechnology, and biochemistry. Volume 84:Issue 7(2020)
• Page Start: 1345
• Page End: 1352
• Publication Date: 2020-07-02
• Subjects: Astragaloside -- central nervous system tumors -- epithelial–mesenchymal transition -- glioma U251 cells -- transforming growth factor-β1; Biotechnology -- Periodicals; Biochemistry -- Periodicals; 660.6
• DOI: 10.1080/09168451.2020.1737502
• Languages: English
• ISSNs: 0916-8451

Abstract

ABSTRACT: Astragaloside IV (AS#IV) has previously demonstrated antitumoractivity. We investigated the effect and mechanisms of AS#IV in relation to epithelial–mesenchymal transition (EMT), viainterference with the Wnt/β-catenin signaling pathway in gliomaU251 cells. Induction of glioma U251 cells by transforming growthfactor (TGF)#β1 activated EMT, including switching E#cadherin toN-cadherin and altering the expression of Wnt/β-catenin signalingpathway components such as vimentin, β-catenin, and cyclin-D1.AS-IV inhibited the viability, invasion, and migration of TGF-β1-induced glioma U251 cells. AS-IV also interfered with the TGF#β1-induced Wnt/β-catenin signaling pathway in glioma U251 cells.These findings indicate that AS#IV prohibits TGF#β1-induced EMTby disrupting the Wnt/β-catenin pathway in glioma U251 cells. AS#IV may thus be a potential candidate agent for treating glioma andother central nervous system tumors. Graphical abstract: Astragaloside IV interfered with the TGF-β1-induced Wnt/β-catenin signaling pathway in glioma cells. uf0001